Organon And Co Revenue Growth Rates (OGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Organon and Co   (NYSE: OGN)
 

OGN's Revenue Growth by Quarter and Year

Organon And Co 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

OGN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1,558.00
1st Quarter March 1,460.00
FY 3,018.00

OGNs Annual Revenue
Organon And Co 's Revenue in the fiscal year 2025 $ 6,216.00 millions
Organon And Co 's Revenue in the fiscal year 2024 $ 6,403.00 millions
Organon And Co 's Revenue in the fiscal year 2023 $ 6,263.00 millions
Organon And Co 's Revenue in the fiscal year 2022 $ 6,174.00 millions
Organon And Co 's Revenue in the fiscal year 2021 $ 6,304.00 millions




OGN Revenue second quarter 2026 Y/Y Growth Comment
Organon And Co reported decrease in Revenue in the second quarter 2026 by -2.26% to $ 1,558.00 millions, from the same quarter in 2025.
The decrease in the second quarter 2026 Organon And Co 's Revenue compares unfavorably to the Company's average Revenue decrease of -0.98%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 140 other companies have achieved higher Revenue growth. While Organon And Co ' s Revenue decline of -2.26% ranks overall at the positon no. 2960 in the second quarter 2026.


OGN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -4.59 % -0.38 % 7.61 %
3rd Quarter September - 1.26 % 4.15 % -1.17 %
2nd Quarter June -2.26 % -0.81 % -0.06 % 1.45 %
1st Quarter March -3.5 % -6.72 % 5.46 % -1.85 %
FY   - -2.73 % 2.24 % -

Financial Statements
Organon And Co 's second quarter 2026 Revenue $ 1,558.00 millions OGN's Income Statement
Organon And Co 's second quarter 2025 Revenue $ 1,594.00 millions Quarterly OGN's Income Statement


OGN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -5.18 % 0.63 % 5.2 %
3rd Quarter September - 0.5 % -1.56 % -5.53 %
2nd Quarter June 6.71 % 5.35 % -0.92 % 4.55 %
1st Quarter March -3.88 % -4.96 % 1.5 % 3.57 %
FY (Year on Year)   - -2.73 % 2.24 % -


Back to OGN Growth rate Comparisons >> Back to OGN Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #141
Healthcare Sector #409
Overall #2960

Revenue Y/Y Growth Statistics
High Average Low
7.61 % -0.98 % -15.39 %
(Sep 30 2024)   (Mar 31 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #141
Healthcare Sector #409
Overall #2960
Revenue Y/Y Growth Statistics
High Average Low
7.61 % -0.98 % -15.39 %
(Sep 30 2024)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Organon And Co 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
6.71 % -0.41 % -14.27 %
(Jun 30 2026)  


OGN's II. Quarter Q/Q Revenue Comment
Organon and Co achieved in the II. Quarter 2026 above company average sequential Revenue increase of 6.71%, to $ 1,558.00 millions, from $1,460.00 millions in the first quarter.
OGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue quarter on quarter growth. While Organon And Co 's Revenue growth quarter on quarter, overall rank is 1023.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #153
Overall #1023
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #153
Overall #1023
Revenue Q/Q Growth Statistics
High Average Low
6.71 % -0.41 % -14.27 %
(Jun 30 2026)  


OGN's II. Quarter Q/Q Revenue Comment
Organon and Co achieved in the II. Quarter 2026 above company average sequential Revenue increase of 6.71%, to $ 1,558.00 millions, from $1,460.00 millions in the first quarter.
OGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Revenue quarter on quarter growth. While Organon And Co 's Revenue growth quarter on quarter, overall rank is 1023.


Organon And Co 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 6,139.00 $ 6,175.00 $ 6,228.00 $ 6,301.00 $ 6,281.00
Y / Y Revenue Growth (TTM) -2.26 % -1.89 % -2.73 % -1.69 % -1.02 %
Year on Year Revenue Growth Overall Ranking # 2534 # 858 # 1317 # 1360 # 1801
Seqeuential Revenue Change (TTM) -0.58 % -0.85 % -1.16 % 0.32 % -0.21 %
Seq. Revenue Growth (TTM) Overall Ranking # 2623 # 946 # 1588 # 1572 # 2016


Cumulative Revenue growth Comment
Organon And Co 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -2.26% year on year, at Jun 30 2026 compare to the -1.89% decrease at Mar 31 2026. If the Organon And Co 's fiscal year would end at Jun 30 2026, annual Revenue would be $6,139 millions.

In the Healthcare sector 365 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 858 to 2534.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 120
Healthcare Sector # 366
Overall # 2534

Revenue TTM Y/Y Growth Statistics
High Average Low
4.21 %
 -0.34 %
-3.46 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 375
S&P 500 # 2623
Cumulative Revenue growth Comment
Organon And Co 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -2.26% year on year, at Jun 30 2026 compare to the -1.89% decrease at Mar 31 2026. If the Organon And Co 's fiscal year would end at Jun 30 2026, annual Revenue would be $6,139 millions.

In the Healthcare sector 365 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 858 to 2534.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 120
Healthcare Sector # 366
Overall # 2534

Revenue TTM Y/Y Growth Statistics
High Average Low
4.21 %
-0.34 %
-3.46 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 120
Sector # 375
S&P 500 # 2623




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OGN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Organon And Co Revenue Growth Rates (OGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Organon and Co (CIK 1821825).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-051230
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Organon and Co’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.